0001143313-18-000054.txt : 20180927
0001143313-18-000054.hdr.sgml : 20180927
20180927132505
ACCESSION NUMBER: 0001143313-18-000054
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20180927
DATE AS OF CHANGE: 20180927
EFFECTIVENESS DATE: 20180927
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOTIME INC
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 181090320
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NYSE AMERICAN LLC
CENTRAL INDEX KEY: 0001143313
IRS NUMBER: 522127241
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-5414
MAIL ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE MKT LLC
DATE OF NAME CHANGE: 20120514
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Amex
DATE OF NAME CHANGE: 20090402
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Alternext US LLC
DATE OF NAME CHANGE: 20081009
25-NSE
1
primary_doc.xml
X0203
0001143313
NYSE AMERICAN LLC
876343
BIOTIME INC
001-12830
1301 Harbor Bay Parkway
Alameda
CA
CALIFORNIA
94502
(972) 533-2820
Common Share Purchase Warrants
17 CFR 240.12d2-2(a)(3)
Victoria Paper
Senior Analyst
2018-09-27
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 8, 2018, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on September 27, 2018 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
Pursuant to the terms of the Warrant Agreement, each warrant to purchase 1.1 shares of BioTime Inc. at an exercise price of $4.55 per share will expire on October 1, 2018.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on September 27, 2018.